Key Highlights

● CareDx was among the Russell 2000's strongest performers on Friday, October 30, 2026.

● Revenue grew sharply.

● The company raised its 2026 outlook.

● Investing.com listed it among top mid-cap gainers.

CareDx (NASDAQ:CDNA) was among the strongest performers on the Russell 2000 on Friday, October 30, 2026, climbing steeply after its quarterly report. Market data listed it among the top mid-cap gainers of the session. Readings of the move differed slightly across sources and times of day, but all showed a powerful rally.

CareDx develops testing services and products for transplant patients, including blood tests that help doctors monitor whether a transplanted organ, such as a kidney or heart, is being rejected. Its Business depends on test volumes, reimbursement and adoption by transplant centers.

The numbers behind the rally

Third-quarter Revenue grew sharply from a year earlier, the kind of acceleration that tends to catch investors' attention in a diagnostics business. CareDx also raised its 2026 revenue guidance to a range of $520 million to $530 million.

A raised outlook this late in the year signals that management has strong visibility into the fourth quarter. For a company whose results depend on testing volumes and payer coverage, an increase in guidance suggests both are trending in its favor. No comments from company executives were found in Friday's coverage.

Health care catches a bid

CareDx's gain came on a day when health care was one of the market's few bright spots. The sector hit a record high, according to market data, as investors rotated out of technology and into more defensive areas. Regeneron (NASDAQ:REGN) jumped to the top of the S&P 500 after strong results, Gilead Sciences (NASDAQ:GILD) rose after beating estimates, and Eli Lilly (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE) and AbbVie (NYSE:ABBV) were among names that touched 52-week highs.

Not every health care stock joined in. Alphatec Holdings plunged after missing estimates and cutting its outlook, Illumina (NASDAQ:ILMN) sank after revenue fell short, and Stryker (NYSE:SYK) dropped after trimming its growth forecast. Those moves showed that investors were rewarding strong numbers within the sector while punishing disappointments.

A difficult backdrop

The broad market had one of its worst sessions of the year. The S&P 500 fell 140.32 points to 7,580.07, the Dow dropped 572.25 points to 51,770.31, and the Nasdaq Composite tumbled 747.73 points to 25,437.00, its worst day since June. The Russell 2000 slid 47.37 points to 2,811.84, though small caps still managed a gain for the week.

The selling was concentrated in chipmakers and big technology companies. Intel (NASDAQ:INTC)'s weak fourth-quarter outlook and warning about cash burn set off a rout in semiconductors, and Amazon (NASDAQ:AMZN)'s results deepened concerns about the cost of AI infrastructure. Crypto stocks fell after Binance reportedly suffered a $6.3 billion hack, and oil climbed above $100 a barrel on tensions around Iran.

Rate expectations added another layer of pressure. The Federal Reserve held its benchmark rate range steady this week, but two officials dissented in favor of an increase and futures markets were pricing a December hike as likely. St. Louis Fed President Alberto Musalem said Friday, "I judge that additional firming of Monetary Policy will be necessary, and soon."

What to watch

For CareDx, the next test is delivering on the raised 2026 guidance of $520 million to $530 million in the fourth quarter. Investors will look for continued growth in testing volumes and any updates on reimbursement, a central Factor for diagnostics companies.

The broader market faces a busy week, with Apple (NASDAQ:AAPL)'s results on Monday, Nov. 2, the midterm elections on Tuesday, Nov. 3, and the October jobs report on Friday, Nov. 6. Whether the rotation into health care continues will be a key theme for the sector in the days ahead.